Ian Bezek

Ian Bezek

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Profit From the Housing Boom With Lowe’s Stock

LOW stock has already enjoyed a solid run in 2020. There's more to come, though, as the work-from-home trend helps Lowe's.

7 Super Stable Dividend Stocks to Buy Now

With the market flying high but risks in the air, this is a great time to play defense by buying these seven super safe dividend stocks.

7 Monthly Dividend Stocks That Will Support Your Retirement

With interest rates reaching record lows, fixed income is no longer a reliable yield provider. These seven monthly dividend stocks could be a great alternative.

FuelCell Energy Isn’t the Right Green Energy Stock

FCEL stock has surged as traders rush into alternative energy stocks. While green companies are promising, FuelCell is not a great choice.

What’s Next For Ocugen After Scoring Orphan Drug Status

Ocugen got a crucial piece of good news from the FDA. But with the company's lead drug years from approval, OCGN stock remains speculative.

Apple Stock Split is Encouraging, but It Can’t Hide Stalled Growth

AAPL stock is reaching new highs after a great earnings report. But don't let the enthusiasm distract you from Apple's unappetizing valuation.

How the Quarantine Era Boosted Purple Innovations in 2020

Purple stock is surging thanks to management's shrewd moves during the pandemic. Now comes the tricky part: keeping that momentum as normalcy returns.

How to Approach Novavax Stock After Tuesday’s 35% Swing

The market went crazy after reports emerged about the safety of Novavax's Covid-19 vaccine. Here's what you need to know about NVAX stock.

Chesapeake Stock: There’s No Turnaround for This Bankrupt Firm

Government filings suggest that Chesapeake stock will soon be worthless. Traders should take heed of that warning.

Amazon Stock Is On the Road to $4,000 After Blowout Earnings

Amazon still has plenty of critics. But while monopoly concerns linger, AMZN stock is still a rock-solid buy after a fantastic earnings beat.